Patent: 10,072,246
✉ Email this page to a colleague
Summary for Patent: 10,072,246
| Title: | Enhanced generation of cytotoxic T lymphocytes by IL-21 mediated FoxP3 suppression |
| Abstract: | A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described. |
| Inventor(s): | Yee; Cassian (Seattle, WA), Li; Yongqing (Shoreline, WA) |
| Assignee: | The Fred Hutchinson Cancer Research Center (Seattle, WA) |
| Application Number: | 15/188,096 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,072,246
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eisai, Incorporated | ONTAK | denileukin diftitox | Injection | 103767 | 02/05/1999 | ⤷ Try a Trial | 2027-10-03 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
